Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2006-10-17 09:48:25 UTC |
---|
Update Date | 2020-04-22 23:33:43 UTC |
---|
HMDB ID | HMDB0005030 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Fexofenadine |
---|
Description | Fexofenadine is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine, an antihistamine with potentially fatal contraindications. Fexofenadine, like other second-generation antihistamines, does not readily enter the brain from the blood, and so causes less drowsiness than first generation histamine receptor antagonists; Fexofenadine hydrochloride (brand names include Allegra and Telfast) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine, an antihistamine with potentially fatal contraindications. Fexofenadine, like other second generation antihistamines, does not readily enter the brain from the blood, and so causes less drowsiness than first-generation histamine-receptor antagonists. |
---|
Structure | CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36) |
---|
Synonyms | Value | Source |
---|
4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid | ChEBI | Carboxyterfenadine | ChEBI | Terfenadine acid metabolite | ChEBI | Terfenadine carboxylate | ChEBI | Terfenadine-COOH | ChEBI | Telfast | Kegg | 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-a,a-dimethylbenzeneacetate | Generator | 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-a,a-dimethylbenzeneacetic acid | Generator | 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetate | Generator | 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-α,α-dimethylbenzeneacetate | Generator | 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-α,α-dimethylbenzeneacetic acid | Generator | Terfenadine carboxylic acid | Generator | Allegra | HMDB, MeSH | Fexofenadine hydrochloride | HMDB, MeSH | Aventis pharma brand OF fexofenadine hydrochloride | MeSH, HMDB | MDL 16,455a | MeSH, HMDB | alpha-(4-(1-Carboxy-1-methylethyl)phenyl)-4-hydroxydiphenylmethyl-1-piperidinebutanol | MeSH, HMDB | Aventis behring brand OF fexofenadine hydrochloride | MeSH, HMDB | Aventis brand OF fexofenadine hydrochloride | MeSH, HMDB | Hoechst brand OF fexofenadine hydrochloride | MeSH, HMDB |
|
---|
Chemical Formula | C32H39NO4 |
---|
Average Molecular Weight | 501.6564 |
---|
Monoisotopic Molecular Weight | 501.287908741 |
---|
IUPAC Name | 2-(4-{1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid |
---|
Traditional Name | fexofenadine |
---|
CAS Registry Number | 83799-24-0 |
---|
SMILES | CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 |
---|
InChI Identifier | InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36) |
---|
InChI Key | RWTNPBWLLIMQHL-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Diphenylmethanes |
---|
Direct Parent | Diphenylmethanes |
---|
Alternative Parents | |
---|
Substituents | - Diphenylmethane
- Phenylbutylamine
- Phenylpropane
- Aralkylamine
- Piperidine
- Tertiary alcohol
- Amino acid or derivatives
- Secondary alcohol
- Amino acid
- Tertiary amine
- Tertiary aliphatic amine
- Azacycle
- Organoheterocyclic compound
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Hydrocarbon derivative
- Organic oxygen compound
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic nitrogen compound
- Organic oxide
- Amine
- Carbonyl group
- Aromatic alcohol
- Alcohol
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 142.5 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 226.9 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Fexofenadine,1TMS,isomer #1 | CC(C)(C(=O)O[Si](C)(C)C)C1=CC=C(C(O)CCCN2CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1 | 4130.8 | Semi standard non polar | 33892256 | Fexofenadine,1TMS,isomer #2 | CC(C)(C(=O)O)C1=CC=C(C(CCCN2CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)O[Si](C)(C)C)C=C1 | 4068.8 | Semi standard non polar | 33892256 | Fexofenadine,1TMS,isomer #3 | CC(C)(C(=O)O)C1=CC=C(C(O)CCCN2CCC(C(O[Si](C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1 | 4125.1 | Semi standard non polar | 33892256 | Fexofenadine,2TMS,isomer #1 | CC(C)(C(=O)O[Si](C)(C)C)C1=CC=C(C(CCCN2CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)O[Si](C)(C)C)C=C1 | 3929.6 | Semi standard non polar | 33892256 | Fexofenadine,2TMS,isomer #2 | CC(C)(C(=O)O[Si](C)(C)C)C1=CC=C(C(O)CCCN2CCC(C(O[Si](C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1 | 3979.0 | Semi standard non polar | 33892256 | Fexofenadine,2TMS,isomer #3 | CC(C)(C(=O)O)C1=CC=C(C(CCCN2CCC(C(O[Si](C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)O[Si](C)(C)C)C=C1 | 3904.9 | Semi standard non polar | 33892256 | Fexofenadine,3TMS,isomer #1 | CC(C)(C(=O)O[Si](C)(C)C)C1=CC=C(C(CCCN2CCC(C(O[Si](C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)O[Si](C)(C)C)C=C1 | 3783.0 | Semi standard non polar | 33892256 | Fexofenadine,1TBDMS,isomer #1 | CC(C)(C(=O)O[Si](C)(C)C(C)(C)C)C1=CC=C(C(O)CCCN2CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1 | 4355.1 | Semi standard non polar | 33892256 | Fexofenadine,1TBDMS,isomer #2 | CC(C)(C(=O)O)C1=CC=C(C(CCCN2CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)O[Si](C)(C)C(C)(C)C)C=C1 | 4287.8 | Semi standard non polar | 33892256 | Fexofenadine,1TBDMS,isomer #3 | CC(C)(C(=O)O)C1=CC=C(C(O)CCCN2CCC(C(O[Si](C)(C)C(C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1 | 4357.0 | Semi standard non polar | 33892256 | Fexofenadine,2TBDMS,isomer #1 | CC(C)(C(=O)O[Si](C)(C)C(C)(C)C)C1=CC=C(C(CCCN2CCC(C(O)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)O[Si](C)(C)C(C)(C)C)C=C1 | 4324.2 | Semi standard non polar | 33892256 | Fexofenadine,2TBDMS,isomer #2 | CC(C)(C(=O)O[Si](C)(C)C(C)(C)C)C1=CC=C(C(O)CCCN2CCC(C(O[Si](C)(C)C(C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)C=C1 | 4417.8 | Semi standard non polar | 33892256 | Fexofenadine,2TBDMS,isomer #3 | CC(C)(C(=O)O)C1=CC=C(C(CCCN2CCC(C(O[Si](C)(C)C(C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)O[Si](C)(C)C(C)(C)C)C=C1 | 4339.3 | Semi standard non polar | 33892256 | Fexofenadine,3TBDMS,isomer #1 | CC(C)(C(=O)O[Si](C)(C)C(C)(C)C)C1=CC=C(C(CCCN2CCC(C(O[Si](C)(C)C(C)(C)C)(C3=CC=CC=C3)C3=CC=CC=C3)CC2)O[Si](C)(C)C(C)(C)C)C=C1 | 4409.8 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (Non-derivatized) - 70eV, Positive | splash10-001i-0912400000-d47ca5514638bcd48093 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (2 TMS) - 70eV, Positive | splash10-001i-1931153000-7fd2e3b3cc17ae068da6 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TBDMS_2_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TBDMS_2_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Fexofenadine GC-MS (TBDMS_3_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , negative-QTOF | splash10-0a6r-0005900000-17ae091cc3d9ba9c62f3 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , negative-QTOF | splash10-0a6r-0396000000-be2d6fedab983b50c280 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , negative-QTOF | splash10-0a4i-1970000000-c78b1c745afc54f58e01 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , negative-QTOF | splash10-0a4r-0920000000-9ad3dc88e743866c23ca | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , negative-QTOF | splash10-0btj-0900000000-66a31911b29382b93745 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , negative-QTOF | splash10-0a4i-1900000000-ce2d00bbddc284806cb0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , positive-QTOF | splash10-0udi-0000090000-2622c1f2ddb4bff3f93d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , positive-QTOF | splash10-0159-0000910000-0afa1079fbe9a822e35c | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , positive-QTOF | splash10-00xr-1920200000-1163d721ce08480aea71 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , positive-QTOF | splash10-00di-1910000000-c593678096415da5efb2 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , positive-QTOF | splash10-002f-2900000000-01de1f32826ab5569301 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine LC-ESI-QFT , positive-QTOF | splash10-002f-3900000000-72f624b2d6e05d29cb72 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine 30V, Negative-QTOF | splash10-0a6r-0296000000-08bc8f52b1adac426d92 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine 45V, Negative-QTOF | splash10-0a4i-1970000000-7a763967a0e22ba5aee4 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine 15V, Negative-QTOF | splash10-0a6r-0004900000-264e1e3683f099cd4d18 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine 45V, Positive-QTOF | splash10-00xr-1920200000-f89d210776b04ca1a4f1 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine 30V, Positive-QTOF | splash10-0159-0000910000-e86af4100fbcd4806c84 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Fexofenadine 15V, Positive-QTOF | splash10-0udi-0000090000-9d409ff3e4f83806f5ac | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fexofenadine 10V, Positive-QTOF | splash10-0f89-0001930000-b9b7ff78564293a249b0 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fexofenadine 20V, Positive-QTOF | splash10-0541-0212900000-ab3069ba65212a7da302 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fexofenadine 40V, Positive-QTOF | splash10-000g-1985500000-f990cf713f3191736f10 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fexofenadine 10V, Negative-QTOF | splash10-0udi-0100690000-e140f2c9a1bcece115e3 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fexofenadine 20V, Negative-QTOF | splash10-0zj0-4223930000-8c8b81776964fc2cb368 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fexofenadine 40V, Negative-QTOF | splash10-004u-9651000000-b823e5714fa6afb8f50f | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Fexofenadine 10V, Positive-QTOF | splash10-0ue9-0000980000-811ef09a2d84417ca55c | 2021-09-22 | Wishart Lab | View Spectrum |
|
---|
General References | - Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
- Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004 Aug;44(8):890-900. [PubMed:15286093 ]
- Simons FE, Silver NA, Gu X, Simons KJ: Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol. 2002 Nov;110(5):777-83. [PubMed:12417888 ]
- Purohit A, Duvernelle C, Melac M, Pauli G, Frossard N: Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol. 2001 Apr;86(4):387-92. [PubMed:11345280 ]
- Inoue T, Katoh N, Kishimoto S, Matsunaga K: Inhibitory effects of oral prednisolone and fexofenadine on skin responses by prick tests with histamine and compound 48/80. J Dermatol Sci. 2002 Dec;30(3):180-4. [PubMed:12443840 ]
|
---|